Norway Infection Control Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product (Disinfectants, Sterilization (Low-Temperature Sterilization, Heat Sterilization, Contract Sterilization)), By End User Industry (Healthcare, Food And Beverage, Chemical) - Forecasts From 2022 To 2027

  • Published : Aug 2022
  • Report Code : KSI061613391
  • Pages : 90

The Norway infection control market is projected to grow at a compound annual growth rate of 6.58% over the forecast period to attain a market size of US$209.261 million in 2027, from US$133.987 million in 2020. The market is poised to grow over the forecast period with the growing number of cancer incidences in the country resulting in cancer treatments. The steady growth in the per capita health spending of Norway is further propagating the market growth in the forecast period. Furthermore, growing research activities will drive market demand over the next five years. Furthermore, the average length of hospital stays in the country is more than 4 days, requiring effective infection control measures to avoid hospital-associated infections. The growing geriatric population is further providing an impetus for the market to thrive in the forecast period and in the upcoming years.

Additionally, the growing research activities are further driving the market demand over the next five years

The growing investments in research and development in Norway are providing an opportunity for the market to thrive in the forecast period. The research investments in trade and industry accounted for a sizable market share, followed by those in higher education and research institutes. It was estimated in 2016 that over 80,000 people were employed in research and development-related activities, out of which more than 60% were scientists. R&D expenditure contributed significantly to the country’s GDP as well. The Research Council of Norway, a national funding agency responsible for basic and practical industry-oriented research, consists of various schemes which include funding opportunities for research projects in addition to network building and centre and tax incentive schemes. The council also provides support to private and public institutions and to several businesses for the development of novel products, procedures, and services based on the research activities, further providing an impetus for the market to grow at a significant pace in the forecast period with the surge in demand for infection control products.

The country's steadily growing per capita health spending is providing an opportunity for the market to grow in the forecast period and in the upcoming years.

As per the European Union estimates, the health spending per capita of the country has grown at a steady pace. This was recorded to be Euro4,459 in 2017, which is around two-thirds more than the EU average. Health spending also accounted for 10.4% of the country’s GDP, above the average EU GDP of 9.8%. The share of public funding in national health expenditure accounts for 85% of the total health spending. This was also reported to be higher than the EU average, i.e. 79%.  Health expenditure is further projected to rise rapidly in the forecast period. The increasing demand for long-term care is one of the major factors contributing to rising healthcare costs.  Also, the country is gearing towards shifting from in-patient to out-patient and community-based settings. However, with the growing awareness of infections among individuals, the market holds strong potential for growth, remaining unaffected by the shift in the trend.

COVID-19 SCENARIO

The market for infection control in Norway has been significantly impacted by the COVID-19 epidemic. Worldwide healthcare systems have been devastated by the pandemic, with hospitals becoming overcrowded as patient numbers rise. Temporary hospitals are being built to handle the influx of cases. The spread of COVID-19 has caused a boom in demand for cleaning and disinfection products because of the heightened awareness about cleanliness, health, and safety. However, it is anticipated that the infection control business will suffer severely in the post-COVID situation.

Key Developments

  • January 2021- FFI and the Norwegian business SoftOx Solutions are collaborating on a new research and development (R&D) initiative with the aim of ensuring the best infection control and wound care for the Norwegian Armed Forces.

Norway Infection Control Market Scope:

 

Report Metric Details
 Market Size Value in 2020  US$133.987 million
 Market Size Value in 2027  US$209.261 million
 Growth Rate  CAGR of 6.58% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Million
 Segments Covered  Product And End User Industry
 Companies Covered  3M, Medtronic, B. Braun Melsungen AG, BD
 Customization Scope  Free report customization with purchase

 

Segmentation:

  • By Product
    • Disinfectant
    • Sterilization
      • Low temperature Sterilization
      • Heat Sterilization
      • Contract Sterilization
  • By End User Industry
    • Healthcare
    • Food and Beverage
    • Chemical

1. Introduction
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1.  Research Data
2.2.  Assumptions

3.  Executive Summary
3.1.  Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4.  Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Norway Infection Control Market by Product
5.1.  Introduction
5.2. Disinfectant
5.3. Sterilization 
5.3.1.  Low-Temperature Sterilization
5.3.2.  Heat Sterilization
5.3.3. Contact Sterilization

6. Norway Infection Control Market by End-User Industry
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical

7. Competitive Environment and Analysis
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3.  Mergers, Acquisitions, Agreements, and Collaborations
7.4.  Vendor Competitiveness Matrix 

8. Company Profiles 
8.1. 3M
8.2. Medtronic
8.3. B. Braun Melsungen AG
8.4. BD

3M

Medtronic

B. Braun Melsungen AG

BD